Teachers Advisors LLC boosted its position in Celgene Corporation (NASDAQ:CELG) by 0.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,136,094 shares of the biopharmaceutical company’s stock after purchasing an additional 1,200 shares during the quarter. Teachers Advisors LLC owned about 0.27% of Celgene Corporation worth $277,415,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of CELG. Oaktop Capital Management II L.P. bought a new stake in Celgene Corporation in the 2nd quarter valued at about $271,605,000. Harbour Capital Advisors LLC raised its position in shares of Celgene Corporation by 12,913.6% during the 2nd quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock worth $12,222,000 after buying an additional 1,575,074 shares in the last quarter. Investec Asset Management LTD bought a new stake in shares of Celgene Corporation during the 1st quarter worth about $194,490,000. Clearbridge Investments LLC raised its position in shares of Celgene Corporation by 24.1% during the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after buying an additional 892,392 shares in the last quarter. Finally, State Street Corp raised its position in shares of Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Hedge funds and other institutional investors own 79.16% of the company’s stock.
Shares of Celgene Corporation (CELG) opened at $104.10 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The stock has a market cap of $81,370.00, a P/E ratio of 15.45, a price-to-earnings-growth ratio of 0.76 and a beta of 1.79. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17.
Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.58 earnings per share. equities research analysts predict that Celgene Corporation will post 6.67 EPS for the current fiscal year.
In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock valued at $2,843,956 over the last quarter. Corporate insiders own 0.95% of the company’s stock.
A number of analysts have commented on CELG shares. Cann restated a “buy” rating and set a $175.00 price target on shares of Celgene Corporation in a research report on Tuesday, August 1st. Jefferies Group LLC restated a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. Mizuho set a $134.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $139.87.
TRADEMARK VIOLATION WARNING: This piece was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://stocknewstimes.com/2017/11/18/teachers-advisors-llc-purchases-1200-shares-of-celgene-corporation-celg.html.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.